Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.

Full acronym for this study: COMMIT - CLEAN SWITCH

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin Detemir; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes

• Patients treated with human soluble insulin, NPH insulin or premixed human insulin

• Patients willing to sign informed consent

• Selection of study participants at the discretion of the physician

Exclusion Criteria:

• Subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30

• Subjects who were previously enrolled in this study

• Subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients